$MNMD News
Last published 10mo ago
- 10mo agoMNMDMindMed to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that Rob
- 11mo agoMNMDMindMed Announces New Employee Inducement GrantBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 11mo agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDMindMed Reports Q3 2025 Financial Results and Business UpdatesBusiness Wire-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- --Anticipated topline data readout from first
- 1y agoMNMDMindMed to Participate in Upcoming Investor ConferencesBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members
- 1y agoMNMDMindMed Announces New Employee Inducement GrantBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDMind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing
- 1y agoMNMDMindMed to Report Q3 2025 Financial Results on November 6, 2025Business WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will
- 1y agoMNMDMind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public OfferingBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing
- 1y agoMNMDMind Medicine (MindMed) Inc. Announces Proposed Public OfferingBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it
- 1y agoMNMDMindMed Announces New Employee Inducement GrantBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDNew MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)Business WireNearly 50% of individuals with severe GAD reported experiencing SI almost daily Findings highlight the link between anxiety severity and SI, underscoring the need for routine screening Researchers from Mind Medicine
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDJournal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)Business WireThe Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a single administration of MM120 across four dose levels, with improvements sustained throughout
- 1y agoMNMDMindMed to Participate in September Investor ConferencesBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDMind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoMNMDMindMed Reports Q2 2025 Financial Results and Business UpdatesBusiness Wire--Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)-- --Data from the Phase 3 Voyage trial in
- 1y agoMNMDMindMed to Report Second Quarter 2025 Financial Results on July 31, 2025Business WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoATAICMPSCYBNMNMD+1Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032GlobeNewswirePALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDMindMed to Participate in June Investor ConferencesBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members
- 1y agoMNMDMindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial OfficerBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDMindMed to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members
- 1y agoMNMDMindMed Reports First Quarter 2025 Financial Results and Recent Business UpdatesBusiness Wire--Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3
- 1y agoMNMDMindMed to Report First Quarter 2025 Financial Results on May 8, 2025Business WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDMindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)Business Wire- Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between MM120 Orally
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance
- 1y agoMNMDMindMed Appoints Matt Wiley as Chief Commercial OfficerBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today
- 1y agoMNMDMindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business UpdatesBusiness Wire--First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for
- 1y agoMNMDMindMed to Present at Leerink's Global Healthcare Conference 2025Business WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members
- 1y agoMNMDMindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025Business WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today
- 1y agoMNMDMindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the
- 1y agoMNMDMindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety DisorderBusiness Wire- Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally
- 1y agoMNMDMindMed to Be Added to the Nasdaq Biotechnology IndexBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced
- 1y agoMNMDMindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)Business Wire- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally
- 1y agoMNMDMindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 CongressBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced
- 1y agoMNMDMindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)Business Wire- Innovation Passport Designation Aims to Accelerate Time to Market and Facilitate Patient Access to Innovative Medicines - Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a
- 1y agoMNMDMindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development StrategyBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced
- 1y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of
- 1y agoMNMDMindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance OfficerBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced
- 1y agoMNMDMindMed to Participate in Upcoming Investor ConferencesBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of
- 2y agoMNMDMind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoMNMDMindMed Reports Third Quarter 2024 Financial Results and Business UpdatesBusiness Wire--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of
- 2y agoMNMDMindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business UpdateBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to
- 2y agoMNMDMindMed Announces New Employee Inducement GrantsBusiness WireMind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of